PHARMACEUTICAL PREPARATION COMPRISING A COMBINATION OF STREPTOCOCCUS STRAINS AND LACTOBACILLUS STRAINS

(19)

(11)

EP 2 349 295 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	14.12.2016 Bulletin 2016/50

(45)	Mention of the grant of the patent:
	26.10.2016 Bulletin 2016/43

(21)	Application number: 09826377.5

(22)	Date of filing: 17.11.2009

(51)

International Patent Classification (IPC):

A61K 35/744^(2015.01)
A61P 11/00^(2006.01)
A61P 31/00^(2006.01)
C12R 1/225^(2006.01)
C12R 1/46^(2006.01)

A61K 35/747^(2015.01)
A61P 31/04^(2006.01)
C12N 1/20^(2006.01)
C12R 1/25^(2006.01)

(86)	International application number:
	PCT/SE2009/051300

(87)	International publication number:
	WO 2010/056198 (20.05.2010 Gazette 2010/20)

(54)

PHARMACEUTICAL PREPARATION COMPRISING A COMBINATION OF STREPTOCOCCUS STRAINS AND LACTOBACILLUS STRAINS

PHARMAZEUTISCHE ZUSAMMENSETZUNGEN MIT EINER KOMBINATION AUS STREPTOKOKKEN- UND LAKTOBAZILLENSTÄMMEN

PRÉPARATION PHARMACEUTIQUE COMPRENANT UNE COMBINAISON DE SOUCHES DE STREPTOCOCCUS ET DE SOUCHES DE LACTOBACILLUS

(84)	Designated Contracting States:
	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

(30)

Priority:

17.11.2008 SE 0850079
17.11.2008 US 115283 P

(43)	Date of publication of application:
	03.08.2011 Bulletin 2011/31

(73)	Proprietor: Winclove Holding B.V.
	1032 LB Amsterdam (NL)

(72)	Inventors:
	Roos, Kristian S-412 71 Göteborg (SE) Grahn Håkansson, Eva S-903 31 Umeå (SE)

(74)	Representative: EP&C
	P.O. Box 3241 2280 GE Rijswijk 2280 GE Rijswijk (NL)

(56)

References cited: :

EP-A1- 1 481 681
WO-A1-98/55131
WO-A1-99/53932
WO-A1-2007/108763
US-A1- 2006 258 596
US-B1- 6 761 885

WO-A1-90/09186
WO-A1-99/07393
WO-A1-2006/054135
WO-A2-2004/030624
US-B1- 6 479 051

PRASHANT K JAIN ET AL: "Influence of synbiotic containing Lactobacillus acidophilus La5, Bifidobacterium lactis Bb 12, Streptococcus thermophilus, Lactobacillus bulgaricus and oligofructose on gut barrier function and sepsis in critically ill patients: a randomised controlled trial", CLINICAL NUTRITION, vol. 23, no. 4, 1 August 2004 (2004-08-01) , pages 467-475, XP55042191, ISSN: 0261-5614, DOI: 10.1016/j.clnu.2003.12.002
ROLFE R D: "THE ROLE OF PROBIOTIC CULTURES IN THE CONTROL OF GASTROINTESTINAL HEALTH", THE JOURNAL OF NUTRITION, WISTAR INSTITUTE OF ANATOMY AND BIOLOGY, vol. 130, no. 2, SUPPL, 1 January 2000 (2000-01-01), pages 396S-402S, XP000978812, ISSN: 0022-3166
HATAKKA K. ET AL: 'Effect of long term consumption of probiotic milk on infections in children attending day care centres: double blind, randomised trial' BMJ vol. 322, 02 June 2001, pages 1 - 5, XP009055425

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).